Market Closed -
Nasdaq
01:30:00 12/06/2024 am IST
5-day change
1st Jan Change
3.04
USD
-2.56%
+3.05%
-26.57%
Relmada Therapeutics, Inc. Announces Resignation of Thomas Wessel as Executive Vice President and Head of Research and Development
January 06, 2021 at 02:32 am IST
On December 31, 2020, Dr. Thomas Wessel, who served as Relmada's Executive Vice President and Head of Research and Development, departed the company.
Goldman Sachs Downgrades Relmada Therapeutics to Sell From Neutral With $2 Price Target
05/06
MT
Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
09/05
Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
09/05
CI
Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024
20/03
Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
20/03
CI
Relmada Says Chief Medical Officer Leaving; Names Senior Clinical Development Advisor
05/01
MT
Relmada Therapeutics, Inc. Announces Resignation of Cedric O?Gorman as Chief Medical Officer
04/01
CI
Transcript : Relmada Therapeutics, Inc., Q3 2023 Earnings Call, Nov 08, 2023
09/11
Relmada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
09/11
CI
Relmada Therapeutics Reports Positive Preclinical Data on its Psilocybin Program to Treat Liver Disease
11/23/11
MT
Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023
11/23/11
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from S&P Global BMI Index
18/23/18
CI
Relmada Therapeutics, Inc. Announces Eric Schmidt to Resign from the Board, Chairman of the Audit Committee of the Board and as A Member of the Corporate Governance and Nominating Committee of the Board
06/23/06
CI
Relmada Therapeutics Doses First Person in Phase 3 Trial of REL-1017 for Major Depressive Disorder
23/23/23
MT
Relmada Therapeutics, Inc. Announces Dosing of First Patient in Relight, a Phase 3 Trial of Relight, a Phase 3 Trial of Relight for the Adjunctive Treatment of Major Depressive Disorder
23/23/23
CI
Transcript : Relmada Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023
09/23/09
Relmada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
09/23/09
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 3000 Index
23/23/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 3000E Value Index
23/23/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell Small Cap Completeness Index
23/23/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 2500 Index
23/23/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 2000 Index
23/23/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 2000 Value Index
23/23/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell Microcap Growth Index
23/23/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 3000E Growth Index
23/23/23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Companyâs lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
More about the company
Last Close Price
3.04
USD
Average target price
10.62
USD
Spread / Average Target
+249.51%
Consensus
1st Jan change
Capi.
-26.57% 9.41Cr +18.34% 12TCr +15.06% 11TCr -6.39% 2.36TCr +2.39% 2.24TCr -12.11% 1.78TCr -41.64% 1.64TCr -12.07% 1.63TCr +1.05% 1.36TCr +25.87% 1.16TCr
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1